Downregulated RBP7 expression was only significantly associated with poor prognosis in ER+/PR+ and ER+/PR− patients but not in ER−/PR+ and ER−/PR− breast cancer patients (Figures 6(e)–6(l)). Here, RBP7 is linked to breast cancer.